In this study we found that blocking the oncogenic Wnt pathway by hsBCL9CT-24 could upregulate chemokine CXCL10 and improve T-cell tumor infiltration in cancer models, which are consistent with a recent report that Wnt pathway activation is linked to primary resistance in immunotherapy (Grasso et al., 2018). Here, CXCL10 is linked to cancer.